



KENNY C. GUINN
Governor

STATE OF NEVADA
DEPARTMENT OF HUMAN RESOURCES
DIVISION OF HEALTH CARE FINANCING AND POLICY
NEVADA MEDICAID

MICHAEL J. WILLDEN
Director

CHARLES DUARTE
Administrator

NOTICE OF OPEN PUBLIC MEETING

The Division of Health Care Financing and Policy ("DHCFP"), Pharmacy and Therapeutics Committee, will conduct a public meeting on **July 14, 2004** beginning at **12:00 p.m.** at the following location:

CARSON CITY
Legislative Building
401 South Carson Street
Room 2135
Carson City

LAS VEGAS
Grant Sawyer Building
555 E. Washington Avenue
Room 4406
Las Vegas

Reasonable efforts will be made to assist and accommodate physically challenged persons desiring to attend the meeting. Please call Nancy Davis at: 775-684-3715 or toll free at: 1-800-992-0900, ext. 43715 in advance, but no later than two working days prior to the meeting, so that arrangements may be conveniently made.

Below is an agenda of all items scheduled to be considered. Unless otherwise noted, items may be taken out of order at the discretion of the Chairperson.

Public comment may be limited to 3 minutes per person or company at the discretion of the Chairperson.

AGENDA

- I. Call to Order and Roll Call
- II. *Review and Approval of June 17th meeting Minutes
- III. Public Comment
- IV. Histamine-Two Receptor Antagonists (H2RA's)
 - A. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
 - B. * Committee Discussion and Approval of Drugs for Inclusion in the PDL
- V. Proton Pump Inhibitors (PPI's)
 - A. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
 - B. * Committee Discussion and Approval of Drugs for Inclusion in the PDL
- VI. Bone Ossification Agents: Bisphosphonates
 - A. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
 - B. * Committee Discussion and Approval of Drugs for Inclusion in the PDL
- VII. Herpetic Antiviral Agents
 - A. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy

1100 E. William Street, Suite 102, Carson City, Nevada 89701
(775) 684-3600

- B. * Committee Discussion and Approval of Drugs for Inclusion in the PDL

- VIII. Hepatitis C Agents
 - A. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
 - B. * Committee Discussion and Approval of Drugs for Inclusion in the PDL

- IX. Cephalosporins Second Generation
 - A. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
 - B. * Committee Discussion and Approval of Drugs for Inclusion in the PDL

- X. Cephalosporins Third Generation
 - A. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
 - B. * Committee Discussion and Approval of Drugs for Inclusion in the PDL

- XI. Macrolides
 - A. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
 - B. * Committee Discussion and Approval of Drugs for Inclusion in the PDL

- XII. Quinolones Second Generation
 - A. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
 - B. * Committee Discussion and Approval of Drugs for Inclusion in the PDL

- XIII. Quinolones Third Generation
 - A. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
 - B. * Committee Discussion and Approval of Drugs for Inclusion in the PDL

- XIV. Glaucoma Agents
 - A. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
 - B. * Committee Discussion and Approval of Drugs for Inclusion in the PDL

- XV. Onychomycosis Agents
 - A. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
 - B. * Committee Discussion and Approval of Drugs for Inclusion in the PDL

- XVI. Low Sedating Antihistamines & Combinations
 - A. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
 - B. * Committee Discussion and Approval of Drugs for Inclusion in the PDL

- XVII. Short Acting Beta-Adrenergics (MDI & Nebulizers)
 - A. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
 - B. * Committee Discussion and Approval of Drugs for Inclusion in the PDL

- XVIII. Long Acting Beta-Adrenergics
 - A. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
 - B. * Committee Discussion and Approval of Drugs for Inclusion in the PDL

- XIX. Inhaled and Nebulized Corticosteroids
 - A. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
 - B. * Committee Discussion and Approval of Drugs for Inclusion in the PDL
- XX. Nasal Steroids
 - A. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
 - B. * Committee Discussion and Approval of Drugs for Inclusion in the PDL
- XXI. Angiotensin Converting Enzyme Inhibitors and Diuretic Combinations
 - A. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
 - B. * Committee Discussion and Approval of Drugs for Inclusion in the PDL
- XXII. Angiotensin II Receptor Blockers and Diuretic Combinations
 - A. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
 - B. * Committee Discussion and Approval of Drugs for Inclusion in the PDL
- XXIII. Calcium Channel Blockers: Dihydropyridine & Non-dihydropyridine
 - A. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
 - B. * Committee Discussion and Approval of Drugs for Inclusion in the PDL
- XXIV. Calcium Channel Blockers and Angiotensin Converting Enzyme Inhibitor Combinations
 - A. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
 - B. * Committee Discussion and Approval of Drugs for Inclusion in the PDL
- XXV. Beta-Blockers and Diuretic Combinations Oral
 - A. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
 - B. * Committee Discussion and Approval of Drugs for Inclusion in the PDL
- XXVI. Lipotropics
 - A. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
 - B. * Committee Discussion and Approval of Drugs for Inclusion in the PDL
- XXVII. Long Acting Narcotics
 - A. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
 - B. * Committee Discussion and Approval of Drugs for Inclusion in the PDL
- XXVIII. Sedative Hypnotics
 - A. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
 - B. * Committee Discussion and Approval of Drugs for Inclusion in the PDL
- XXIX. Serotonin Reuptake Inhibitors
 - A. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
 - B. * Committee Discussion and Approval of Drugs for Inclusion in the PDL
- XXX. New Generation Antidepressants
 - A. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy

- B. * Committee Discussion and Approval of Drugs for Inclusion in the PDL
- XXXI. Stimulants/ADHD Drugs
 - A. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
 - B. * Committee Discussion and Approval of Drugs for Inclusion in the PDL
- XXXII. Review of October 28th Meeting Location, Date, and Time
- XXXIII. Public Comment
- XXXIV. *Adjournment

*** Denotes items, including subparts, on which an action may be taken.**

This notice and agenda has been posted on or before 9:00 a.m. on the third working day before the meeting at the following locations:

Notice of this meeting will be available on or after the posting date of this Agenda at the DHCFP Web site (dhcfp@state.nv.us).

Posting of the Agenda will be at the Nevada Medicaid Central offices in Carson City and Las Vegas; Nevada State Library; Carson City Library; Churchill County Library; Las Vegas Library; Douglas County Library; Elko County Library; Lincoln County Library; Lyon County Library; Mineral County Library; Tonopah Public Library; Pershing County Library; Goldfield Public Library; Eureka Branch Library; Humboldt County Library; Lander County Library; Storey County Library; Washoe County Library; and White Pine County Library and may be reviewed during normal business hours.

If requested in writing, a copy of the action items will be mailed to you or they may be reviewed Monday through Friday from 9:00 a.m. until 5:00 p.m., or at the meeting. Please call at least one day ahead for an appointment for document review. Written comments on the proposed changes may be sent to the DHCFP, 1100 E. William Street, Suite 102, Carson City, NV 89701.

All persons that have requested in writing to receive the Open Meeting Agenda have been duly notified by mail or e-mail.

Anyone presenting documents for consideration during the public comment portion of the meeting must provide sufficient copies for each member of the committee and the official record. Copies are to be distributed at the time of the meeting and should be provided at both meeting locations; DHCFP or its contractor will not distribute public comment information or materials prior to the public meeting.